Keros Therapeutics

Keros Therapeutics: clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematologic and musculoskeletal disorders with high unmet medical need. We are a leader in understanding the role of the Transforming Growth Factor-Beta family of proteins that is a master regulator of red blood cell and platelet production as well as the growth, repair and maintenance of muscle and bone. Our lead protein therapeutic product candidate, KER-050, is being developed for the treatment of cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndrome and myelofibrosis. Our lead small molecule product candidate, KER-047, is being developed for the treatment of anemia resulting from elevated levels of hepcidin, the key regulator of iron absorption and recycling, as well as for the treatment of fibrodysplasia ossificans progressiva.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
US - New England
Clinical Stage
Phase l or ll
Disease Space
Metabolic Disorders, Oncology, Rare Disease
Listing
Public, USA
Market Cap
1B +
Website:
Profiles:
Address:
99 Hayden Avenue
Suite 120 (Building E)
Lexington, MA 02421
United States

Company Participants at Solebury Trout Virtual Management Access Event 2021

Jasbir Seehra
Keros Therapeutics, CEO
Jasbir Seehra is the founding CEO of Keros Therapeutics. Jas worked with the academic founders and Pontifax in putting together the strategy and in-licensing of the founding technology. Jas brings more than 30 years of scientific, strategic and operational experience in Biotech industry. Prior to Keros, Seehra was the CSO at Ember Therapeutics,
Keith Regnante
Keros Therapeutics, CFO
Keith Regnante has served as our Chief Financial Officer since February 2020. Prior to joining us, from August 2016 to January 2020, Mr. Regnante served as Chief Financial Officer at Wave Life Sciences Ltd. From February 2014 to August 2016, Mr. Regnante served as Vice President of Finance at Shire Pharmaceuticals, or Shire, a global biopharmaceutical company. Mr. Regnante also served on the Financial Leadership Team and the R&D Leadership Team while he was at Shire. From September 2013 to February 2014, he served as Head of R&D Finance for ARIAD Pharmaceuticals, Inc. From January 1999 to August 2013, Mr. Regnante held multiple finance positions at Biogen Inc., including Senior Director of Corporate Finance from 2011 to 2013, Senior Director of Worldwide R&D Finance from 2008 to 2011 and several other positions dating back to 1999. Prior to joining finance organizations for biotechnology companies, Mr. Regnante worked as a consultant at The Boston Consulting Group. He holds a B.A. in Economics from Tufts University and an M.B.A. from the MIT Sloan School of Management.

Top 10 Holders of Keros Therapeutics, Inc.

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Fidelity Management & Research Co. LLC 13.16 2,644,620 171.11 13F 12/31/20
OrbiMed Advisors LLC 8.36 1,679,417 108.66 13F 12/31/20
Foresite Capital Management IV LLC 7.03 1,412,705 91.40 13F 12/31/20
VR Adviser LLC 3.35 672,306 43.50 13F 12/31/20
BlackRock Fund Advisors 3.30 663,229 42.91 13F 12/31/20
The Vanguard Group, Inc. 2.98 599,454 38.78 Funds 1/31/21
Vanguard Group, Inc. (Subfiler) 2.79 559,910 36.23 13F 12/31/20
Consonance Capital Management LP 2.77 557,095 36.04 13F 12/31/20
Nantahala Capital Management LLC 2.66 534,514 34.58 13F 12/31/20
Logos Global Management LP 2.24 450,000 29.12 13F 12/31/20
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2021 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.